Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

  • Ana C. Garrido-Castro (Creator)
  • Cristina Saura (Creator)
  • Romualdo Barroso-Sousa (Creator)
  • Hao Guo (Creator)
  • Eva Ciruelos (Creator)
  • Begoña Bermejo (Creator)
  • Joaquin Gavilá (Creator)
  • Violeta Serra (Creator)
  • Aleix Prat (Creator)
  • Laia Paré (Creator)
  • Pamela Céliz (Creator)
  • Patricia Villagrasa (Creator)
  • Yisheng Li (Creator)
  • Jennifer Savoie (Creator)
  • Zhan Xu (Creator)
  • Carlos L. Arteaga (Creator)
  • Ian E. Krop (Creator)
  • David B. Solit (Creator)
  • Gordon B. Mills (Creator)
  • Lewis C. Cantley (Creator)
  • Eric P. Winer (Creator)
  • Nancy U. Lin (Creator)
  • Jordi Rodon (Creator)
  • Aleix Prat (Creator)

Dataset

Description

Abstract Background Treatment options for triple-negative breast cancer remain limited. Activation of the PI3K pathway via loss of PTEN and/or INPP4B is common. Buparlisib is an orally bioavailable, pan-class I PI3K inhibitor. We evaluated the safety an...
Date made available2020
Publisherfigshare Academic Research System

Access Dataset

Cite this